Nigeria right now is losing ground on Lassa fever and not in case numbers alone, but in survival odds.
The Nigeria Centre for Disease Control and Prevention reported this week that the Case Fatality Rate for the 2026 Lassa fever outbreak has climbed to 25%, up sharply from 18.9% recorded across the same period in 2025. In practical terms, one in four confirmed patients is dying. A year ago, that figure was closer to one in five. The gap between those two statistics represents a measurable deterioration in Nigeria’s ability to manage a disease it has been battling for more than five decades.
The broader numbers reinforce the concern. As of Week 23, covering June 1 to 7, confirmed deaths have reached 214, with active cases spread across 23 states and 109 local government areas. Five states, Ondo, Bauchi, Taraba, Edo, and Benue, account for 84% of confirmed cases, though the geographic reach of the outbreak signals that Lassa fever is no longer a regional problem contained to familiar hotspots.
A rising CFR is rarely about the disease getting stronger. It is more often a signal of systemic strain. Patients are arriving at health facilities too late for intervention, diagnostic capacity are not keeping pace with case volume, or treatment infrastructure that was never built to absorb an outbreak of this scale. Nigeria has had confirmed Lassa fever outbreaks every single year for decades now. The persistence of those structural gaps is what makes the 2026 figures difficult to explain away as an anomaly.
There is one point of measured progress in the NCDC’s Week 23 situation report. No new healthcare worker infections were recorded during the reporting period, suggesting that infection prevention protocols within clinical settings are holding. That is meaningful, but it really does not offset the overall trend. Protecting health workers while patients continue to die at an accelerating rate is not a containment success.
The NCDC’s Incident Management System remains active, and surveillance continues across affected states. But surveillance that consistently documents worsening outcomes without a corresponding reversal in fatality trends raises a harder question: at what point does data collection need to translate into structural change?
Lassa fever has never attracted the international urgency of Ebola or the domestic media attention of cholera outbreaks. It moves quietly through rural communities, kills steadily, and recedes before the next season brings it back. That cycle has continued long enough. A CFR of 25% in 2026 is not a warning signal. It is evidence that the warnings have already been ignored.
